Literature DB >> 28135142

How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

Sibylle Loibl1, Carsten Denkert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28135142     DOI： 10.1200/JCO.2016.71.3503

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620.

Authors:  Michael Untch; Sibylle Loibl; Peter A Fasching
Journal:  Breast Care (Basel)       Date:  2019-06-04       Impact factor: 2.860

2.  Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.

Authors:  Mads H Haugen; Ole Christian Lingjærde; Ingrid Hedenfalk; Øystein Garred; Elin Borgen; Niklas Loman; Thomas Hatschek; Anne-Lise Børresen-Dale; Bjørn Naume; Gordon B Mills; Gunhild M Mælandsmo; Olav Engebraaten
Journal:  JCO Precis Oncol       Date:  2021-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.